MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-19-2022
Calliditas Therapeutics AB (publ) Revenue 2011-2026 | CALT
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Calliditas Therapeutics AB (publ)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 874 K | 185 M | - | - | - | - | - | - | - | - |
All numbers in SEK currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 185 M | 874 K | 92.9 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Drug manufacturers industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
28 K | - | 7.5 % | $ 6.35 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
194 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
19.6 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
4.76 M | - | 0.86 % | $ 117 M | USA |
 |
DURECT Corporation
DRRX
|
8.55 M | - | - | $ 50.1 M | USA |
 |
Cronos Group
CRON
|
46.7 M | $ 2.65 | -1.85 % | $ 1.36 B |  Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
10.4 M | $ 4.28 | 2.15 % | $ 60.2 M | USA |
 |
Catalent
CTLT
|
4.38 B | - | - | $ 11.5 B | USA |
 |
Alimera Sciences
ALIM
|
80.8 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
103 M | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
317 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
2.01 B | - | - | $ 28.9 M |  Irlanda |
 |
Avadel Pharmaceuticals plc
AVDL
|
169 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
5.18 M | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
191 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Bausch Health Companies
BHC
|
8.76 B | $ 5.67 | 1.61 % | $ 2.07 B | Canada |
 |
Canopy Growth Corporation
CGC
|
269 M | $ 1.15 | -4.17 % | $ 124 M | Canada |
 |
Jupiter Wellness
JUPW
|
2.12 M | - | - | $ 33.6 M | USA |
 |
Harrow Health
HROW
|
272 M | $ 40.48 | -2.25 % | $ 1.49 B | USA |
 |
Lannett Company
LCI
|
341 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
160 M | $ 1.4 | -2.78 % | $ 402 M | Canada |
 |
Evolus
EOLS
|
297 M | $ 5.27 | 0.96 % | $ 340 M | USA |
 |
Sundial Growers
SNDL
|
946 M | $ 1.47 | -2.65 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
1.05 B | $ 8.23 | 2.49 % | $ 421 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
925 K | - | - | $ 193 M | Canada |
 |
Organogenesis Holdings
ORGO
|
482 M | $ 2.4 | 0.42 % | $ 316 M | USA |
 |
Pacira BioSciences
PCRX
|
542 M | $ 25.41 | -0.55 % | $ 1.18 B | USA |
 |
Radius Health
RDUS
|
230 M | - | - | $ 1.42 B | USA |
 |
ProPhase Labs
PRPH
|
123 M | - | - | $ 5.07 M | USA |
 |
cbdMD
YCBD
|
19.5 M | $ 0.91 | -6.19 % | $ 3.92 M | USA |
 |
Assertio Holdings
ASRT
|
119 M | $ 18.04 | - | $ 116 M | USA |
 |
PetIQ
PETQ
|
1.1 B | - | 1.64 % | $ 400 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
14.3 M | $ 1.04 | -6.31 % | $ 1.29 M | USA |
 |
Relmada Therapeutics
RLMD
|
5.13 K | $ 7.24 | 2.99 % | $ 286 M | USA |
 |
Tilray
TLRY
|
627 M | $ 6.56 | -4.79 % | $ 4.05 B | Canada |
 |
Recro Pharma
REPH
|
94.6 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
71 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
20.6 M | $ 0.99 | -1.42 % | $ 49.4 M | USA |
 |
PLx Pharma
PLXP
|
8.21 M | - | -27.8 % | $ 2.56 M | USA |
 |
Veru
VERU
|
16.9 M | $ 2.29 | -2.14 % | $ 309 M | USA |
 |
Viatris
VTRS
|
15.4 B | $ 14.82 | 0.07 % | $ 17.8 B | USA |
 |
Aurora Cannabis
ACB
|
175 M | $ 3.42 | -2.56 % | $ 86.3 M | Canada |
 |
Zomedica Corp.
ZOM
|
32 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
86 K | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
69.3 M | $ 0.89 | 5.24 % | $ 32 M | USA |
 |
China Pharma Holdings
CPHI
|
4.14 M | $ 0.56 | -4.13 % | $ 2.4 M |  China |
 |
TherapeuticsMD
TXMD
|
3.02 M | $ 2.1 | 1.45 % | $ 24.3 M | USA |